Lung Cancer News

In this edition, a phase 3 trial of a regimen for small cell lung cancer misses its co-primary endpoint; obesity and pulmonary function may identify the need for home oxygen after lung cancer surgery; a study finds that lung cancer screening is less common among those most likely to benefit from it; and more.

Men, smokers and younger patients with non-small cell lung cancer all appeared to derive more benefit from immunotherapy, according to a systematic review published in JNCI Cancer Spectrum.

A novel PD-1/CTLA-4 bispecific checkpoint inhibitor demonstrated antitumor activity and tolerability among patients with advanced solid tumors, according to study results.

The FDA granted priority review to trastuzumab deruxtecan for treatment of adults with unresectable or metastatic HER2-mutated non-small cell lung cancer, according to a press release from the agent’s manufacturer.

Plinabulin demonstrated similar efficacy to pegfilgrastim for the prevention of chemotherapy-induced neutropenia, according to results of a randomized phase 3 study published in JAMA Network Open.

Patients with non-small cell lung cancer exhibited less depression and anxiety when receiving treatment during the COVID-19 pandemic than healthy individuals, according to a study in Journal of National Comprehensive Cancer Network.

The FDA granted orphan drug designation to serplulimab for treatment of small cell lung cancer.

An artificial intelligence model appeared to predict adverse events associated with novel combination therapies for various cancer types, according to study results presented at American Association for Cancer Research Annual Meeting.

Neoadjuvant nivolumab plus chemotherapy significantly improved EFS in stage IB to stage IIIA resectable non-small cell lung cancer, according to research presented at American Association for Cancer Research Annual Meeting.

Patients with non-small cell lung cancer and an exceptionally high anti-PD-1 therapy response more frequently had a variant of the CTLA-4 gene, which may be used to identify those who may benefit from such treatment.